ClinicalTrials.gg
CompletedNCT00522925Updated Sep 16, 2011Results posted

A Trial to Evaluate the Safety and Efficacy of PS433540 to Treat Hypertension

A Phase 2 interventional study of PS433540 and placebo in Hypertension, sponsored by Ligand Pharmaceuticals. Completed at 15 sites in United States. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2011-09-16.

Sponsored by Ligand Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
280
Allocation
Randomized
Ages
30 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 2,031 studies in Hypertension with a site in United States — 272 open to participants now, 369 under way, 16 of them phase 3. Hypertension · United States.

Enrollment
519th of 1,779
280 · median 100
Started
2007
with 72 others
Phase 2
170 of 2,031
21 open now
Registered
339th of 2,031
by date

Among the 2,031 studies in Hypertension with a site in United States, this one is the 519th largest by enrollment of the 1,779 interventional ones that give a count, is one of 73 that started in 2007, is one of 170 in phase 2, and was the 339th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.

Browse Hypertension studies →

Open to participants now

272 of the 2,031 studies in Hypertension with a site in United States are open now. Recruiting first, the newest first:

267 more — sign in →

All 272 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 30 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,031 studies in Hypertension with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to see if PS433540 lowers blood pressure better than placebo and to see how safe PS433540 is compared to placebo.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • hypertension
  • high blood pressure
04

Who can participate

Ages eligible
30 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females 30 - 80 years
  • Mean seated Systolic Blood Pressure (SBP) ≥ 150 - ≤ 179 mmHg and mean seated DBP \< 110 mmHg at two consecutive qualifying visits. The mean difference in SBP between the two consecutive qualifying visits must be ≤ 10 mmHg.
  • Mean daytime (8AM - 4PM) ambulatory SBP must be between ≥ 140 - ≤ 179 mmHg and mean daytime (8AM - 4PM) Diastolic Blood Pressure (DBP) ≤ 110 mmHg
  • Subjects must have a usual daytime schedule. Night shift workers are excluded from participation.
  • Women of (WOCBP) and male subjects must use two reliable forms of if sexually active. Alternatively, female subjects must be (for at least 1 year)

Exclusion criteria

Exclusion Criteria:

  • Subjects with serious disorders which may limit the ability to evaluate the efficacy or safety of PS433540, including cardiovascular, renal (including the absence of one kidney), pulmonary, hepatic, gastrointestinal (including malabsorption), endocrine/metabolic, hematologic/oncologic (including an active other than basal cell carcinoma), neurologic and psychiatric diseases.
  • Subjects with a history of myocardial infarction, angina, coronary angioplasty, bypass surgery or (NYHA) class II-IV heart failure within the last 6 months.
  • Subjects with a history of cerebrovascular accident or within the last 1 year.
  • Subjects with diabetes mellitus (type I and type II).
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
280 participants (actual)

Study arms

  • Placebo comparator
    1

    Matching Placebo

    Drug: placebo

  • Experimental
    2

    Drug: PS433540

  • Experimental
    3

    Drug: PS433540

Interventions

  • 200mg capsule, once daily for 28 days

  • Drugplacebo

    placebo capsule, once daily for 28 days

  • 500mg capsule, once daily for 28 days

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Mean 24-hour Ambulatory Systolic Blood Pressure

    Time frame: 4 weeks of treatment with PS43540

Secondary outcomes

  1. Change From Baseline in Mean 24-hour Ambulatory Diastolic Blood Pressure

    Time frame: 4 weeks of treatment with PS43540

  2. Change From Baseline in Mean Seated Systolic and Diastolic Blood Pressure

    Time frame: 4 weeks of treatment with PS43540

07

Results

Posted Sep 14, 2011

Participant flow

Participant flow — Overall Study
Milestone1- Placebo2- PS433540 200mg3- PS433540 500mg
Started363938
Completed283836
Not completed812

Outcome measures

PrimaryChange From Baseline in Mean 24-hour Ambulatory Systolic Blood Pressure
Time frame:
4 weeks of treatment with PS43540
Reported as:
Mean · mmHg
Change From Baseline in Mean 24-hour Ambulatory Systolic Blood Pressure
mmHg1- Placebo2- PS433540 200mg3- PS433540 500mg
Change From Baseline in Mean 24-hour Ambulatory Systolic Blood Pressure-0.3 (-4.8 to 4.2)-11.9 (-15.3 to -8.6)-15.3 (-18.8 to -11.8)
SecondaryChange From Baseline in Mean 24-hour Ambulatory Diastolic Blood Pressure
Time frame:
4 weeks of treatment with PS43540

Results for this outcome have not been posted.

SecondaryChange From Baseline in Mean Seated Systolic and Diastolic Blood Pressure
Time frame:
4 weeks of treatment with PS43540

Results for this outcome have not been posted.

Adverse events

Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
1- Placebo—1/36 (2.8%)9/36 (25%)
2- PS433540 200mg—1/39 (2.6%)8/39 (20.5%)
3- PS433540 500mg—0/38 (0%)10/38 (26.3%)
Most frequent serious events
Most frequent serious events
Event1- Placebo2- PS433540 200mg3- PS433540 500mg
SyncopeCardiac disorders1/360/390/38
Basal Cell CarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/361/390/38
Most frequent other events
Showing 10 of 12
Most frequent other events
Event1- Placebo2- PS433540 200mg3- PS433540 500mg
HeadacheNervous system disorders4/362/393/38
Back PainMusculoskeletal and connective tissue disorders3/361/390/38
NasopharyngitisInfections and infestations2/361/392/38
Confusional StatePsychiatric disorders2/360/390/38
RhinorrhoeaRespiratory, thoracic and mediastinal disorders2/360/390/38
FatigueGeneral disorders1/362/390/38
Upper Respiratory Tract InfectionInfections and infestations1/361/391/38
Blood Pressure IncreaseInvestigations1/361/390/38
Oedema PeripheralCardiac disorders1/360/391/38
Dyspnoea ExertionalRespiratory, thoracic and mediastinal disorders1/360/391/38

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)1- Placebo2- PS433540 200mg3- PS433540 500mgTotal
<=18 years0000
Between 18 and 65 years30273188
>=65 years612725
Age Continuous
Age Continuous(years)1- Placebo2- PS433540 200mg3- PS433540 500mgTotal
Mean58.4 ± 7.9459.1 ± 8.7256.8 ± 9.8758.1 ± 8.84
Sex: Female, Male
Sex: Female, Male(Participants)1- Placebo2- PS433540 200mg3- PS433540 500mgTotal
Female12181040
Male24212873
Region of Enrollment
Region of Enrollment(participants)1- Placebo2- PS433540 200mg3- PS433540 500mgTotal
United States363938113
08

Study locations

15 sites
  • Premiere Pharmaceutical Research, LLC
    Tempe, Arizona 85282, United States
  • Clinical Trials Research
    Lincoln, California 95648, United States
  • Long Beach Center for Clinical Research
    Long Beach, California 90806, United States
  • National Research Institute
    Los Angeles, California 90057, United States
  • Sacramento Research Medical Group
    Sacramento, California 95825, United States
  • Orange County Research Center
    Tustin, California 92780, United States
  • Westlake Medical Center
    Westlake Village, California 91361, United States
  • University Clinical Research Deland, LLC
    Deland, Florida 32720, United States
  • Alan Graff, MD PA
    Fort Lauderdale, Florida 33308, United States
  • Cedar Crosse Research Center
    Chicago, Illinois 60607, United States
  • Orland Primary Care Specialists
    Orland Park, Illinois 60467, United States
  • MD Medical Research
    Oxon Hill, Maryland 20745, United States
  • Lindner Clinical Trial Center
    Cincinnati, Ohio 45219, United States
  • Punzi Medical Center
    Carrolton, Texas 75006, United States
  • Gemini Scientific
    Madison, Wisconsin 53719, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2007, a primary completion of Apr 2008 and a completion of May 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2011, 3 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2007
First posted
Aug 30, 2007
Start
Aug 2007
Primary completionActual
Apr 2008
CompletionActual
May 2008
Results first posted
Sep 14, 2011
Last update
Sep 16, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00522925
Responsible party
Sponsor
First posted
Aug 30, 2007
Start date
Aug 2007
Primary completion
Apr 2008
Completion
May 2008
Results posted
Sep 14, 2011
Last update
Sep 16, 2011

Study contacts

Joel M Neutel, MD
principal investigator · Integrium

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sparsentan

Start the discussion